The $49M in Series A funding will be used to develop the company’s enzyme replacement therapies for two rare diseases affecting infants and children and push the treatments into the clinic.
Source: BioSpace
The $49M in Series A funding will be used to develop the company’s enzyme replacement therapies for two rare diseases affecting infants and children and push the treatments into the clinic.
Source: BioSpace